Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects

Capmatinib is a highly specific, potent, and selective mesenchymal–epithelial transition factor inhibitor predominantly eliminated by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. Here, we investigated the effects of a strong CYP3A inhibitor (itraconazole) and a strong CYP3A inducer (rifampicin) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Xiaoming, Chen, Xinhui, Pognan, Nathalie, Sengupta, Tirtha, Rahmanzadeh, Gholamreza, Kornberger, Ruediger, Giovannini, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092221/
https://www.ncbi.nlm.nih.gov/pubmed/36087217
http://dx.doi.org/10.1002/jcph.2153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092221/
https://www.ncbi.nlm.nih.gov/pubmed/36087217
http://dx.doi.org/10.1002/jcph.2153

Ejemplares similares